Outro
New York, US · Founded 2022 · 2 known investors
Outro is a telehealth program that pairs patients with a dedicated clinician to safely taper off antidepressants using the evidence-based hyperbolic tapering method, including compounded doses, symptom monitoring, and between-visit support. It serves individuals in the United States looking to reduce or stop psychiatric medications, and plans to expand to benzodiazepines and gabapentinoids.
Founders & leadership
BS
Brandon Strain-GoodeNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.8M disclosed across 1 round · 2024
▶$2.8MraisedOct 2024 · 22 investors · Other Health CareRule 506(b)
▶$2.8MraisedOct 2024 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Brandon Strain-GoodeExecutive Officer, Director
- Offering amount
- $2.9M
- Amount sold
- $2.8M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Outro do?
- Outro is a telehealth program that pairs patients with a dedicated clinician to safely taper off antidepressants using the evidence-based hyperbolic tapering method, including compounded doses, symptom monitoring, and between-visit support. It serves individuals in the United States looking to reduce or stop psychiatric medications, and plans to expand to benzodiazepines and gabapentinoids.
- Who are Outro's investors?
- Outro's investors include Hannah Grey Ventures, SemperVirens Venture Capital.
- How much funding has Outro raised?
- Outro has disclosed $2.8M raised across 1 round.
- Where is Outro headquartered?
- Outro is headquartered in New York, US.